ID

34401

Descrizione

Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib; ODM derived from: https://clinicaltrials.gov/show/NCT01514448

collegamento

https://clinicaltrials.gov/show/NCT01514448

Keywords

  1. 17/01/19 17/01/19 -
Titolare del copyright

see on clinicaltrials.gov

Caricato su

17 gennaio 2019

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0

Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Metastatic Renal Cell Carcinoma (mRCC) NCT01514448

Eligibility Metastatic Renal Cell Carcinoma (mRCC) NCT01514448

Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients with advanced renal cell carcinoma of a histological or cytological confirmation of clear cell renal carcinoma.
Descrizione

ID.1

Tipo di dati

boolean

progression during or after a treatment with sunitinib or pazopanib given in a 1st line treatment situation for mrcc.
Descrizione

ID.2

Tipo di dati

boolean

patients scheduled for treatment with everolimus.
Descrizione

ID.3

Tipo di dati

boolean

patients with at least one measurable lesion at baseline.
Descrizione

ID.4

Tipo di dati

boolean

Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients who have received >1 prior systemic treatment for their metastatic rcc. prior systemic treatment in an adjuvant setting is allowed.
Descrizione

ID.5

Tipo di dati

boolean

patients who have previously received systemic mtor inhibitors (e.g. sirolimus, temsirolimus, everolimus).
Descrizione

ID.6

Tipo di dati

boolean

patients who are using other investigational agents or who had received investigational drugs ≤ 2 weeks prior to study treatment start.
Descrizione

ID.7

Tipo di dati

boolean

patients unwilling or unable to comply with the protocol.
Descrizione

ID.8

Tipo di dati

boolean

other protocol-defined inclusion/exclusion criteria may apply.
Descrizione

ID.9

Tipo di dati

boolean

Similar models

Eligibility Metastatic Renal Cell Carcinoma (mRCC) NCT01514448

Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
patients with advanced renal cell carcinoma of a histological or cytological confirmation of clear cell renal carcinoma.
boolean
ID.2
Item
progression during or after a treatment with sunitinib or pazopanib given in a 1st line treatment situation for mrcc.
boolean
ID.3
Item
patients scheduled for treatment with everolimus.
boolean
ID.4
Item
patients with at least one measurable lesion at baseline.
boolean
Item Group
C0680251 (UMLS CUI)
ID.5
Item
patients who have received >1 prior systemic treatment for their metastatic rcc. prior systemic treatment in an adjuvant setting is allowed.
boolean
ID.6
Item
patients who have previously received systemic mtor inhibitors (e.g. sirolimus, temsirolimus, everolimus).
boolean
ID.7
Item
patients who are using other investigational agents or who had received investigational drugs ≤ 2 weeks prior to study treatment start.
boolean
ID.8
Item
patients unwilling or unable to comply with the protocol.
boolean
ID.9
Item
other protocol-defined inclusion/exclusion criteria may apply.
boolean

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial